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Article / Clinical Case Report
ABSTRACT
Neurofibrosarcoma is a rare malignant neoplasm of the head and neck region and accounts for 8% to 16% of all 
cases. Its origin is varied and may stem from cells of the peripheral nerves, develop de novo, or result from malignant 
transformation of preexisting neurofibromas. Because the features of neurofibrosarcomas are heterogeneous, the data 
retrieved during clinical examinations are of great aid for diagnosis. In this case, owing to clinical features and the fact 
that the patient had neurofibromatosis type 1, the hypothesis of neurofibrosarcoma was promptly established. The final 
diagnosis was confirmed by associating clinical, imaging, and pathological data. After the treatment, the patient has 
been followed up for 10 years, with no evidence of recurrence. 
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INTRODUCTION
Neurofibrosarcoma (NFS), also known as malignant 
schwannoma or peripheral nerve sheath malignancy, is 
a rare malignant neoplasm of the head and neck region 
and accounts for 8% to 16% of all cases.1 Its origin 
is varied. Some may stem from cells of peripheral 
nerves,2 develop de novo,3 or arise from malignant 
transformations of preexisting neurofibromas.1,3 It is 
estimated that 50% of the cases are diagnosed in 
patients with neurofibromatosis type 1 (NF-1), which 
is also known as von Recklinghausen’s disease.1,3-5 
Neurofibromatosis (NF) is an autosomal dominant, 
high-penetrance disease with a varied expression, 
with NF-1 being the most common, accounting for 
85% to 90% of cases. It is considered that 10% of 
patients with NF-1 develop NFS.5 The treatment of 
choice for NFS is surgery, with or without radio- and 
chemotherapy. The prognosis is usually poor and may 
present locoregional or distant metastases, mainly to 
the lungs.6
NFS features are heterogeneous. Therefore, 
the data provided by the clinical examination are 
important, especially the presence of neurofibromas 
or other characteristics of the NF-1, thus directing the 
diagnostic hypotheses.
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CASE REPORT
A 14-year-old girl presented with the chief 
complaint of “increasing of neck volume and 
tooth mobility” with intense pain and left lower 
lip paresthesia over the last 6 months. During the 
anamnesis, the mother reported that the patient had 
NF-1, diagnosed in childhood, but did not present the 
classical signs of neurofibromas, café au lait macules, 
or Lisch nodules.
On examination, facial asymmetry was observed 
because of an increased volume of the mandible and 
the left submandibular region, which extended from 
the chin to the angle of the mandible. The skin was 
normal, and the regional lymph nodes presented 
inflammatory features. The intraoral examination of 
the corresponding lesion revealed an erythematous 
bulging lesion of the buccal and lingual cortical bone, 
with central necrosis in the left posterior mandible 
that extended from the canine to the second molar. 
Easy bleeding occurs on tooth dislocation (Figure 1).
Computed tomography revealed the rupture of 
the lingual and buccal cortical bone. The tumor was 
a solid lesion with a density similar to that of the 
soft tissues (Figure 2A and 2B). Similarly, magnetic 
resonance imaging (MRI) presented the involvement 
of the buccal and lingual lesion (Figure 2C and 2D).
Figure 1. Intraoral examination shows a bulging lesion 
with central necrosis erupting the buccal and lingual 
cortical bone.
Figure 2. A and B - Axial computed tomography of the mandible revealing the rupture of the lingual and buccal 
cortical bone. C and D - Facial magnetic resonance imaging C axial plane and D coronal plane. Images weighted in 
T2 revealing the size and the projection of the buccal and lingual lesion.
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The three-dimensional reconstruction clearly 
illustrates the tumor extent, showing irregular bone 
resorption and destruction of the basal mandible 
(Figure 3).
Due to these clinical features, and the patient’s 
previous diagnosis of NF-1, the hypothesis of NFS was 
established and an incisional biopsy was performed. 
The anatomopathological examination showed a 
tumor with high cellularity, composed of irregularly 
organized spindle cells with occasional “spine” and 
some “Verocay-like” forms, arranged in loose and 
myxoid areas in an abrupt transition. The nuclei were 
intensely atypical and exhibited hyperchromatism, 
pleomorphism, and occasional mitotic figures. There 
was necrosis in up to 20% of the tumor extent 
(Figure 4).
The immunohistochemical panel was characterized 
by the focal positivity for vimentin, HHF-35, and 
p53 actin and negativity for S-100, desmin, and CD99 
(Figure 5). The Ki-67 was positive in 95% to 98% of 
the tumor cells.
The final diagnosis of NFS was established by 
associating the clinical, imaging, and pathological data. 
The treatment of choice was neoadjuvant chemotherapy 
and segmental mandibulectomy (Figure 6). After 
surgery, chemotherapy and adjuvant radiotherapy were 
performed. The patient has been in the follow-up for 
10 years, with no evidence of recurrence.
Figure 3. Three-dimensional reconstruction of the mandible illustrating the tumor extent with irregular bone 
resorption.
Figure 4. Photomicrographs of the tumor. A - Cellular arrangements in loose bundles, perivascular disposition, 
and areas of myxoid aspect. The cells are elongated, with poorly defined borders, and the nuclei are equally 
elongated and atypical (HE, 400×). B - Cellular arrangements in bundles with occasional “fishbone” arrangement, 
fibrosarcoma-like. Note the presence of mitoses (HE, 400×).
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DISCUSSION
NFS may present unusual clinical and imaging 
features.1 The clinical characteristic of NFS is its rapid 
growth, either asymptomatic or painful, accompanied 
by paresthesia, muscular atrophy, and weakness. The 
tumor margins are irregular, and there may be ulcerations 
on the surface.3 In this case, the patient complained of 
pain and lip paresthesia, and the surface was ulcerated.
The mandible, lip, and buccal mucosa are the most 
commonly involved sites in the oral cavity affected by 
NFS.1 Intraosseous NFS of the mandible may present 
with an increased volume of the mandibular canal or 
mental foramen.7,8 In some cases, the radiographic 
findings suggest malignancy as an irregularity of the 
margins of the lesion.7 In our case, we could observe the 
extensive destruction of the mandibular base, the loss 
of the mandibular canal definition, and the ill-defined 
margins observed on imaging examinations.
Histologically, NFS is composed of spindle 
cells, with elongated, rounded, or bulky nuclei, 
presenting hyperchromatism and varying degrees 
of pleomorphism.1,3 The stroma is usually fibrotic or 
myxomatous where heterotrophic elements such as 
mature bone or cartilaginous islets, skeletal muscle, 
glands and sites of hemorrhage, and necrosis can be 
found.3 The presence of spindle cells with atypical 
nuclei in our case was consistent with a lesion of 
malignant mesenchymal origin, that is, a sarcoma. 
The final diagnosis of NFS by conventional methods 
of anatomic-pathological examination is difficult to 
establish1 because the characteristics are similar to those 
of other sarcomas that present spindle cell proliferation 
such as fibrosarcoma, leiomyosarcoma, monophasic 
synovial sarcoma, epithelioid sarcoma, and malignant 
fibrous histiocytoma.1,5,7 Usually, the only histological 
distinction between these sarcomas and NFS is their 
Figure 5. Photomicrographs of the tumor. A - Streptavidin-biotin-peroxidase. Mayer’s hematoxylin and 
diaminobenzidine. Occasional vimentin positivity. B - Streptavidin-biotin-peroxidase. Mayer’s hematoxylin 
and diaminobenzidine. Ki-67 proliferative index. C - Streptavidin-biotin-peroxidase. Mayer’s hematoxylin and 
diaminobenzidine. Negativity to desmin.
Figure 6. A - Intraoperative view of the segmental mandibulectomy. B - Resected surgical.
Araujo JP, Oliveira JX, Lanel V, Marcuccib M
5-6Autops Case Rep (São Paulo). 2019 Oct-Dec;9(4):e2019094
origin of nerve branches,9 which was not observed in 
our case.
The precise diagnosis can be established with the aid 
of the electron microscopy and immunohistochemistry. 
The biological marker mostly used is S-100, which is 
positive in 17% to 56% of cases of NFS.10,11 It is a specific 
protein for nerve tissue12 and is observed in numerous 
cells originating from the neural crest, including 
Schwann cells.1 The immunohistochemical panel of this 
case showed negativity for the S-100 protein, which as 
already mentioned, is negative in approximately 50% 
of cases; focal positivity for the intermediate vimentin 
filament, present in fibroblasts, demonstrating the 
mesenchymal origin of the tumor; and negativity for 
desmin present in smooth and skeletal muscles, thus 
ruling out the muscular origin of the tumor. Positivity 
for the Ki-67 protein and proliferative index of 95% to 
98% demonstrated rapid growth and aggressiveness 
of the tumor. The final diagnosis was established 
as NFS according to the morphologic features and 
immunohistochemical panel.
There are different points of view regarding the 
treatment of NFS. Radical surgery is imperative1,3, and 
complementary radiotherapy increases the patient’s 
survival rate by 5 years.13,14 Radiotherapy may also be 
used in cases of local recurrence and inoperable tumors.3 
Some authors argue that using radiotherapy as the first 
treatment method leads to poor results15 and supports 
postsurgical radiation.16 In a study17 of head and neck 
sarcomas, the authors proposed combined surgery 
and radiotherapy in cases of advanced tumors (larger 
than 5 cm), whereas they opted for only surgery for 
lesions of smaller sizes. In cases of total irresectability 
of the tumor, palliative radiotherapy and chemotherapy 
sessions were provided.17 In some studies13,18, the 
indication of chemotherapy is controversial. The patient 
was initially treated with neoadjuvant chemotherapy 
to reduce the lesion size, followed by radical surgery 
with free margins, associated with radiotherapy and 
chemotherapy. This method was chosen based on the 
tumor extent (larger than 5 cm), its aggressive behavior 
with high Ki-67, and its high indices of locoregional and 
distant recurrences and metastases, which represents 
approximately 33% of cases.16,19
High rates of recurrence following multimodality 
therapy in early disease, low response rates to cytotoxic 
chemotherapy in advanced disease, and propensity for 
rapid disease progression and high mortality19 make 
the prognosis of NFS poor19-21, with a 5-year survival 
rate ranging from 15% to 30%21 for patients with 
NF-1. Locoregional or distant metastasis may occur4,5 
mainly in the lungs.6 The lymph nodes are rarely 
affected.1,6,14 The development of new, worsening, or 
persistent pain in the neurofibroma of a patient with 
NF-1 is an important symptom that should always 
be conscientiously evaluated.19 Our patient has been 
followed up for 10 years, with no evidence of recurrence 
or metastasis, possibly because of better investigation 
and fast intervention at earlier stages of disease in 
patients with NF-1 due to improvements in imaging 
and diagnostic techniques.
NFS may present different clinical and imaging 
features, with MRI being the most useful imaging 
modality for characterizing the anatomical extent of the 
tumor.19 The biopsy is fundamental for the final diagnosis. 
Despite the fact that anatomopathological presentation 
is very similar to other sarcomas, immunohistochemistry 
is usually necessary to confirm the diagnosis. In the 
present case, knowing that the patient had NF-1, 
NFS was the initial working diagnosis.
The patient’s mother signed the consent declaration 
after this research was approved by the Research Ethical 
Committee of the Hospital.
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